|
KMID : 0931320230230030174
|
|
대한상부위장관.헬리코박터학회지
2023 Volume.23 No. 3 p.174 ~ p.179
|
|
|
Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori Eradication
|
|
Ahn Byeong-Yun
Cho Soo-Jeong
|
|
|
Abstract
|
|
|
|
The escalating prevalence of clarithromycin resistance in cases of Helicobacter pylori, insufficient acid suppression, and pharmacodynamic variations secondary to inter-individual differences in CYP2C19 polymorphism collectively contribute to suboptimal eradication rates observed with proton pump inhibitor (PPI)-based therapy. Compared with PPIs, potassium-competitive acid blockers (PCABs) produce rapid, potent, and long-lasting suppression of gastric acid through reversible inhibition of gastric H+, K+-ATPase. PCAB-based therapy results in significant inhibition of acid secretion and has therefore emerged as a novel and effective approach for H. pylori eradication. In this study, we review the efficacy and safety profile of PCAB-based eradication regimens comprising vonoprazan, tegoprazan, and fexuprazan.
|
|
|
KEYWORD
|
|
|
Drug resistance, microbial, Drug therapy, Gastric acid, Helicobacter pylori, Proton pump inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|